This transcript has been edited for clarity.
Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. Joining me today is Dr Marco Valgimigli, who is an extraordinary leader in the field of antiplatelet therapy. He's from Lugano, Switzerland.
We are just wrapping up the ESC Congress, and one of the big topics of conversation was the results of a trial that he led, the MASTER DAPT trial, which was an investigator-initiated study and his passion for several years. We're going to talk about that trial and its practice implications. There's been a large amount of chat about that. Welcome, Marco.
Marco Valgimigli, MD, PhD: Thank you very much, Michelle, for having me.
O'Donoghue: Perhaps as a first step, would you like to walk people through the study design? I know that the results have also just been published in The New England Journal of Medicine, so again, congratulations.
Valgimigli: Thank you very much. We set up this study a few years ago to focus on patients who are at high risk for bleeding (HBR) complications who are undergoing PCI for either chronic or acute coronary syndromeThe key question in our mind was how long we should use DAPT. There have been many retrospective studies showing that perhaps, specifically in HBR patients, the DAPT duration could be shortened without compromising safety and gaining with respect to bleeding liability. However, no prospective study had ever tested that.
COMMENTARY
Is 1-Month Dual Antiplatelet Therapy Safe? Reconciling MASTER DAPT and STOPDAPT-2
Michelle L. O'Donoghue, MD, MPH; Marco Valgimigli, MD, PhD
DisclosuresSeptember 13, 2021
This transcript has been edited for clarity.
Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. Joining me today is Dr Marco Valgimigli, who is an extraordinary leader in the field of antiplatelet therapy. He's from Lugano, Switzerland.
We are just wrapping up the ESC Congress, and one of the big topics of conversation was the results of a trial that he led, the MASTER DAPT trial, which was an investigator-initiated study and his passion for several years. We're going to talk about that trial and its practice implications. There's been a large amount of chat about that. Welcome, Marco.
Marco Valgimigli, MD, PhD: Thank you very much, Michelle, for having me.
O'Donoghue: Perhaps as a first step, would you like to walk people through the study design? I know that the results have also just been published in The New England Journal of Medicine, so again, congratulations.
Valgimigli: Thank you very much. We set up this study a few years ago to focus on patients who are at high risk for bleeding (HBR) complications who are undergoing PCI for either chronic or acute coronary syndromeThe key question in our mind was how long we should use DAPT. There have been many retrospective studies showing that perhaps, specifically in HBR patients, the DAPT duration could be shortened without compromising safety and gaining with respect to bleeding liability. However, no prospective study had ever tested that.
© 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michelle L. O'Donoghue, Marco Valgimigli. Is 1-Month Dual Antiplatelet Therapy Safe? Reconciling MASTER DAPT and STOPDAPT-2 - Medscape - Sep 13, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Michelle L. O'Donoghue, MD, MPH
Senior Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School; Associate Physician, Brigham and Women's Hospital, Boston, Massachusetts
Disclosure: Michelle L. O'Donoghue, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Janssen; Novartis; CVS Minute Clinic
Received research grant from: Merck & Co., Inc.; GlaxoSmithKline; Eisai Inc.; AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals; Medicines Company; Amgen
The opinions expressed in this article are solely my own and do not necessarily reflect the views and opinions of Brigham and Women's Hospital.
Marco Valgimigli, MD, PhD
Associate Professor, Department of Cardiology; Senior Interventional Cardiologist, Department of Cardiothoracic Surgery, Inselspital Universitätsspital Bern, Bern, Switzerland
Discosure: Marco Valgimigli, MD, PhD, has disclosed no relevant financial relationships.